Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Edward Boghosian who wrote (1656)	10/28/1999 9:13:00 AM
From: celeryroot.com	Read Replies (1) \| Respond to of 2173

SAN DIEGO, Oct. 28 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced positive results from a Phase 2 study of its second diabetes drug candidate, AC2993 (synthetic exendin-4), in people with type 2 diabetes. In this crossover study, participants received subcutaneous AC2993 or placebo twice daily for five days. On the first and last days of the study, a standard liquid meal was ingested. The plasma glucose concentration during the first five hours following the meals was reduced on average by 34% (from 213 to 141 mg/dL) when participants were treated with AC2993 compared to placebo (p=0.0001). The 24 participants included people who used diet and exercise to manage their diabetes, those who used oral hypoglycemic agents, and those who used insulin. The dose of AC2993 used was 0.1 microgram per kilogram of body weight. The safety and tolerability profile observed in this single-blind, placebo-controlled study was similar to that in previous studies. "Because type 2 diabetes is a progressive disorder, the finding that AC2993 lowered glucose in study participants at each stage of type 2 diabetes is important in characterizing the effects of AC2993," commented John Buse, MD, PhD, University of North Carolina Diabetes Care Center, Chapel Hill, North Carolina. Amylin Pharmaceuticals plans to submit the results of this study for presentation to international diabetes conferences. Additional Phase 2 studies of AC2993 in people with type 2 diabetes are to begin later this quarter. Amylin Pharmaceuticals, Inc. is a development pharmaceutical company focused on metabolic disorders, and specializing in preclinical characterization of lead molecules and demonstration of proof of principle in humans. The Company has pioneered research of the hormone amylin and is developing SYMLIN(TM) (pramlintide acetate), a synthetic analog of human amylin, for the treatment of diabetes in people using insulin. The Company recently announced positive results from a one-year, US Phase 3 study of SYMLIN in type 2 diabetes. The results of the Company's ongoing one-year Phase 3, US study of SYMLIN in type 1 diabetes are planned to be reported later this year. AC2993 is being evaluated in type 2 diabetes and related metabolic disorders. The Company has successfully completed a Phase 1 safety and tolerability trial and an initial dose-finding clinical study of AC2993 in people with type 2 diabetes. The Company has demonstrated that AC2993 is biologically active in animal models when administered via noninjectable routes. The Company is currently engaged in partnership discussions for SYMLIN and AC2993. Amylin Pharmaceuticals is headquartered in San Diego, California. Further information on the Company and its development pipeline is available at http://ww